GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Valuation Rank

Nektar Therapeutics (LTS:0UNL) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Nektar Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (LTS:0UNL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Valuation Rank
Comparable Companies
SLDB VNDA VTYX AVIR QTTB MRSN FHTX XOMA PSTX XERS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
NKTR:USA ITH:Germany
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Website
https://www.nektar.com
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.